Home › Bacterial Infections › NCT04263792
[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects
RecruitingPhase 1
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * At least 18 years of age * Known or suspected bacterial infection, per clinical documentation of suspected infection (e.g. lab results, pathology results, physician progress notes, clinical symptoms of infection) * Able to understand the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures Exclusion Criteria: * Antibiotic therapy with trimethoprim within 48h of the baseline PET/CT scan * Inability to tolerate imaging procedures, in the opinion of an investigator or treating physician * Unstable or other severe medical or psychological comorbidities that would compromise the subject's safety or successful participation in the study, in the opinion of an investigator or treating physician * Pregnant or breast feeding patients; a urine pregnancy test will be performed in women of child-bearing potential prior to \[18F\]F-TMP injection, to confirm non-pregnant status
About the study
The purpose of this study is to study a radioactive tracer, a type of imaging drug that is injected into the body to see how it is taken up in sites of active infection using an imaging procedure called Positron Emission Tomography/Computed Tomography (PET/CT).
What is being tested
- [18F]fluoropropyl-trimethoprim (drug)
Sponsor: University of Pennsylvania · Participants: 20 · Started: Feb 7, 2020
Contact the study team
- Erin Schubert · Phone: 215-662-3041
Official record on ClinicalTrials.gov — NCT04263792
Locations in the U.S.
| Pennsylvania | University of Pennsylvania, Philadelphia |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.